Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | LIFR | P42702 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002899 | 1.00 | NR1H4 (0.56) | NR1H4PPARDLIFR | |
| SCHEMBL12572015 | 1.00 | NR1H4 (0.56) | NR1H4PPARDLIFR | |
| SCHEMBL1096077 | 0.87 | NR1H4 (0.70) | NR1H4PPARDLIFR | |
| SCHEMBL18724953 | 0.82 | NR1H4 (0.49) | NR1H4 | |
| SCHEMBL12168743 | 0.77 | NR1H4 (0.67) | NR1H4PPARDLIFR | |
| SCHEMBL3451972 | 0.77 | ALDH1A1 (0.57) | NR1H4 | |
| SCHEMBL3638644 | 0.75 | GHSR (0.50) | NR1H4 | |
| SCHEMBL23773958 | 0.75 | NR1H4 (0.67) | NR1H4PPARDLIFR | |
| SCHEMBL2001485 | 0.75 | NR1H4 (0.61) | NR1H4PPARDLIFR | |
| SCHEMBL1179026 | 0.74 | NR1H4 (0.67) | NR1H4PPARDLIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120775-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885PPARD 114/4885LIFR 2399/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885PPARD 114/4885LIFR 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.